Bifurcations of optimal vector fields in the shallow lake model

The solution structure of the set of optimal solutions of the shallow lake problem, a problem of optimal pollution management, is studied as we vary the values of the system parameters: the natural resilience, the relative importance of the resource for social welfare and the future discount rate. We find parameter values at which qualitative changes occur. Using theoretical results on the bifurcations of the solution structure to infinite horizon optimization problems obtained earlier, we give a fairly complete bifurcation analysis of the shallow lake problem. In particular, we show how the increase of the discount rate affects the parameter regions where an oligotrophic steady state, corresponding to low pollution level, is globally stable or locally stable under optimal dynamics. Asymptotically, an increase of the discount rate can be offset with a proportional increase of the relative social weight of the resource.

Bifurcations of optimal vector fields in the shallow lake system

The shallow lake problem is a nonconvex production-pollution dynamic optimisation problem whose solution structure depends nonlinearly on the system parameters. We perform a bifurcation analysis to investigate the consequences of varying the relative cost of pollution and the discount rate.

High resolution, low temperature photoabsorption cross-section of C2H2 with application to Saturn's atmosphere

New laboratory observations of the VUV absorption cross-section of C2H2, obtained under physical conditions approximating stratospheres of the giant planets, were combined with IUE observations of the albedo of Saturn, for which improved data reduction techniques have been used, to produce new models for that atmosphere. When the effects of C2H2 absorption are accounted for, additional absorption by other molecules is required. The best-fitting model also includes absorption by PH3, H2O, C2H6 and CH4. A small residual disagreement near 1600 A suggests that an additional trace species may be required to complete the model

Orthotopic liver transplantation in U.S. veterans under primary tacrolimus immunosupression.

The evolution and refinement of surgical techniques, per ioperative patient care, and immunosuppression hav~ estab~ished orthoto~ic li~er transplantation (OLTX) as a ~ighly successful therapeutic modality for patients wrth end-stage hver disease. In February 1989,Tacrohmus (Prograf®, formerly FK 506)was first used successfully at the University of Pittsburgh Medical Center to treat patients with rejection refractory to cyclosporine-based immunosuppression." Clinical trials utilizing Tacrolimus in solid organ transplantation followed, and in April of 1994 it was approved for use by the Food and Drug Administration

Hepatitis C virus genotypes in liver transplant recipients: Impact on posttransplant recurrence, infections, response to interferon-α therapy and outcome

Background. End-stage liver disease due to hepatitis C virus (HCV) is the most common indication for liver transplantation in U.S. veterans. We investigated the influence of HCV genotypes on the incidence and timing of recurrent HCV hepatitis, survival, infectious morbidity, and response to interferon-α therapy in this unique patient population. Methods. HCV genotype was determined by direct sequencing of the NS5 region of HCV with type-specific primers. Results. Genotype 1a (66%, 32/47) was the predominant genotype. Type 1b was found in 25% (12/47) of patients and type 2b was found in 9% (4/47). His topathologically recurrent HCV hepatitis developed in 53% (25/47) of the patients after transplantation. This group included 45% (14/31) of the patients with type 1a, 67% (8/12) of the patients with type 1b, and 25% (1/4) of the patients with type 2b (P>0.5). The time to recurrence and the severity of HCV recurrence as defined by aminotransferase levels or Knodell scores were not different among the three genotypes. There was a trend toward a higher incidence of major infections in patients with type 1b (75%) versus type 1a (48%) and type 2b (50%) (P=0.11). The response to interferon-α therapy did not differ significantly among the genotypes. Mortality at 5 years was 16% (5/31) in patients with genotype 1a, 42% (5/12) in patients with genotype 1b, and 50% (2/4) in patients with genotype 2b (P=0.06). Conclusions. The incidence, time to recurrence, and response to interferon-α therapy did not differ be tween the various genotypes in our liver transplant recipients. However, there was a trend toward higher infectious morbidity and overall mortality in patients with genotype 1b after transplantation